113860-07-4

Usage

Uses

Used in Catalysis:
CHLORO(PENTAMETHYLCYCLOPENTADIENYL)RUTHENIUM(II) TETRAMER is used as a catalyst in various chemical reactions due to its ability to facilitate transformations under mild conditions. Its unique electronic and steric properties make it suitable for promoting specific catalytic cycles, enhancing reaction rates, and improving selectivity.
Used in Materials Science:
In the field of materials science, CHLORO(PENTAMETHYLCYCLOPENTADIENYL)RUTHENIUM(II) TETRAMER is utilized for the development of new materials with tailored properties. Its incorporation into materials can lead to novel electronic, optical, and magnetic characteristics, making it a valuable component in the design of advanced materials for various applications.
Used in Electrochemistry:
CHLORO(PENTAMETHYLCYCLOPENTADIENYL)RUTHENIUM(II) TETRAMER is employed in electrochemical processes, where it can serve as an active component in electrocatalytic systems. Its redox properties and stability make it a promising candidate for applications such as energy storage and conversion, including batteries and fuel cells.
Used in Organic Synthesis:
This ruthenium compound is used as a reagent or catalyst in organic synthesis to enable new synthetic pathways and improve the efficiency of existing ones. Its ability to activate and transform organic substrates under controlled conditions contributes to the development of more sustainable and selective chemical processes.
Used in Pharmaceutical Research:
In pharmaceuticals, CHLORO(PENTAMETHYLCYCLOPENTADIENYL)RUTHENIUM(II) TETRAMER is studied for its potential therapeutic applications. Ruthenium complexes, including this tetrameric form, are being investigated for their bioactivity, with the aim of discovering new drugs or drug delivery systems that can target specific diseases or conditions.

InChI:InChI=1/4C10H15.4CH3.4ClH.4Ru/c4*1-6-7(2)9(4)10(5)8(6)3;;;;;;;;;;;;/h4*1-5H3;4*1H3;4*1H;;;;/q;;;;;;;;;;;;4*+1/p-4/r4C10H15.4CH3ClRu/c4*1-6-7(2)9(4)10(5)8(6)3;4*1-3-2/h4*1-5H3;4*1H3

Upstream product

• 132664-85-8 (5-methylpyrazine-2-yl)methylamine 
• 1138555-04-0 ethyl 2-(4-methyl-1,4-diazepan-1-yl)-5-oxo-5H-benzo[4,5]thiazolo-[3,2-a][1,8]-naphthyridine-6-carboxylate 
• 58584-83-1 2,6-dichloronicotinoyl chloride 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 881633-93-8 ethyl 2-chloro-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxylate 

Relevant academic research and scientific papers

CRYSTALLINE FORMS OF QUINOLINE ANALOGS AND SALTS THEREOF, COMPOSITIONS, AND THEIR METHODS FOR USE

The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I). Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms and the compositions thereof.

Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics

Accelerated proliferation of solid tumor and hematologic cancer cells is linked to accelerated transcription of rDNA by the RNA polymerase I (Pol I) enzyme to produce elevated levels of rRNA (rRNA). Indeed, upregulation of Pol I, frequently caused by mutational alterations among tumor suppressors and oncogenes, is required for maintenance of the cancer phenotype and forms the basis for seeking selective inhibitors of Pol I as anticancer therapeutics. 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c] fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (CX-5461, 7c) has been identified as the first potent, selective, and orally bioavailable inhibitor of RNA Pol I transcription with in vivo activity in tumor growth efficacy models. The preclinical data support the development of CX-5461 as an anticancer drug with potential for activity in several types of cancer.

Facile and efficient generation of quinolone amides from esters using aluminum chloride

Quinolone esters are readily converted into the corresponding amides using aluminum chloride at room temperature in excellent yields and purities. The method is both general and scalable to multi-kilogram quantities.

QUINOLONE ANALOGS AND METHODS RELATED THERETO

The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.